Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Exondys 51 Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0135

    Exondys 51

    Customize your policy alerts

    Sign up for Cigna Policy IP0135 alerts

    Get alerted when Policy IP0135 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Exondys 51 (eteplirsen intravenous infusion) for patients with Duchenne muscular dystrophy. Coverage applies when the genetic, functional, age, specialist-prescribing, dosing, and other policy criteria are met.

    Policy Summary
    PayerCigna
    PolicyExondys 51
    Policy CodePolicy IP0135
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 22, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of the qualifying DMD variant, ambulation, and baseline 6-minute walk test results for initial therapy.
    SourceLink
    POLICY UPDATE CHANGES

    Initial therapy criteria added a requirement that Duchenne muscular dystrophy be confirmed by a pathogenic or likely pathogenic DMD gene variant amenable to exon 51 skipping.

    Initial therapy criteria added a requirement that the patient was younger than 14 years at the start of therapy.

    Initial therapy criteria added an ambulation requirement for the patient to be able to walk.

    The initial therapy ambulation criterion changed from independently walking at least 180 meters over 6 minutes to being able to walk with submission of baseline 6-minute walk test results.

    Initial therapy criteria added that the patient must not have received Elevidys.

    Examples of exon-skipping therapies were moved to a note under Conditions Not Covered.

    30 mg/kgExondys 51 dose
    Once weeklyInfusion frequency
    6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approval duration
    <14 yearsAge at therapy start
    Exon 51DMD gene target

    Coverage Criteria

    FDA-approved indication: Duchenne muscular dystrophy

    Covered for the FDA-approved indication when either the initial-therapy or continuation-therapy pathway is met.

    Duchenne muscular dystrophy coverage pathways

    • Initial Therapy: Approve for 6 months when all of the following are met: the patient is less than 14 years of age at the start of therapy; Duchenne muscular dystrophy is confirmed by a pathogenic or likely pathogenic variant in the DMD gene amenable to exon 51 skipping; the patient is able to walk and submits baseline six-minute walk test results; the patient has not received Elevidys; and the medication is prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association clinic.
    • Currently Receiving Exondys 51: Approve for 6 months when all of the following are met: Duchenne muscular dystrophy is confirmed by a pathogenic or likely pathogenic variant in the DMD gene amenable to exon 51 skipping; the patient was less than 14 years of age at the start of therapy; the patient is able to walk; and the medication is prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association clinic.

    Dosing

    The established dosing regimen is required; an out-of-range dose may be reviewed case by case.

    Dosing: Administer Exondys 51 at 30 milligrams per kilogram once weekly as a 35- to 60-minute intravenous infusion.30 mg/kg once weekly; 35 to 60 minutes

    Doses outside the established regimen may be considered case by case by a Medical Director or Pharmacist.

    Initial Therapy

    Initial therapy criteria

    All initial therapy requirements: The patient has not received Elevidys; Duchenne muscular dystrophy is confirmed by a pathogenic or likely pathogenic variant in the DMD gene amenable to exon 51 skipping; the patient was younger than 14 years of age at the start of therapy; the patient is able to walk; and baseline six-minute walk test results are submitted.Age <14 years at start of therapy

    Documentation is required for genetic confirmation, ambulation, and baseline 6MWT results.

    For initial Exondys 51 therapy, the patient must not have previously received Elevidys.

    Concurrent use of Exondys 51 with another exon-skipping Duchenne muscular dystrophy agent is not supported because there is no clinical evidence supporting concurrent exon-skipping therapy for DMD.

    Initial therapy may not be covered when the patient has received Elevidys.

    Exondys 51 is considered not medically necessary for uses outside the covered FDA-approved Duchenne muscular dystrophy indication, including concurrent use with other exon-skipping DMD agents.

    Coding and Coverage Details

    Considered Medically Necessary when criteria in the applicable policy statements listed above are metHCPCSCovered
    J1428Injection, eteplirsen, 10 mg
    Considered Medically Necessary HCPCS CodesHCPCSCovered
    J1428Injection, eteplirsen, 10 mg
    Patient age at start of therapy
    Initial-therapy age thresholdPatient is less than 14 years of age at the start of therapy.
    Continuation-therapy age thresholdPatient must have been less than 14 years of age at the start of therapy.
    Approval durationCoverage may be approved for 6 months when the applicable therapy criteria are met.
    Exondys 51 dose
    Dose30 mg/kg
    FrequencyOnce weekly
    Administration

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Exondys 51. Approval requires that the applicable coverage criteria and established dosing be met; requests for doses outside the policy dosing are reviewed case by case.

    • Standard dosing: 30 mg/kg administered once weekly as a 35- to 60-minute intravenous infusion.
    Documentation Required

    Specialist Prescribing Requirement

    Exondys 51 must be prescribed by, or in consultation with, a physician who specializes in the condition being treated.

    • Qualifying prescriber or consultant: neurologist, neuromuscular specialist, or Muscular Dystrophy Association (MDA) clinic.

    Disease and Treatment Background

    Duchenne muscular dystrophy is an X-linked recessive disease caused by pathogenic variants in the DMD gene. These variants are associated with loss of dystrophin in muscle cells.

    Definitions

    6MWT
    Term6MWT means six-minute walk test.
    PurposeUsed to document baseline walking ability and functional status.
    Coverage useBaseline 6MWT results must be submitted for initial therapy.
    Mutation amenable to exon 51 skipping
    TermMutation amenable to exon 51 skipping.
    DefinitionA DMD-gene mutation whose predicted effect can be addressed by skipping exon 51 during dystrophin mRNA processing.
    Treatment relevanceExondys 51 is designed to promote exclusion of exon 51 during dystrophin mRNA processing in patients with amenable mutations.

    Initial Therapy Criteria

    Initial Therapy

    Approve for 6 months when all initial-therapy criteria are met.

    Initial Exondys 51 therapy: The patient is less than 14 years of age at the start of therapy; has Duchenne muscular dystrophy confirmed by a pathogenic or likely pathogenic DMD-gene variant amenable to exon 51 skipping; is able to walk and submits baseline six-minute walk test results; has not received Elevidys; and receives the medication prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association clinic.<14 years at start of therapy

    Documentation is required for the genetic diagnosis and baseline 6MWT results.

    Initial Therapy

    Coverage for initial therapy requires all of the following criteria.

    Initial therapy requirements: The patient has not received Elevidys; Duchenne muscular dystrophy is confirmed by a pathogenic or likely pathogenic variant in the DMD gene amenable to exon 51 skipping; the patient was younger than 14 years of age at the start of therapy; the patient is able to walk; and baseline six-minute walk test results are submitted.

    Continuation Therapy Criteria

    Currently Receiving Exondys 51

    Approve for 6 months when the patient is currently receiving Exondys 51 and meets all continuation criteria.

    Continuation therapy: The patient has Duchenne muscular dystrophy confirmed by a pathogenic or likely pathogenic DMD-gene variant amenable to exon 51 skipping; was less than 14 years of age at the start of therapy; is able to walk; and receives the medication prescribed by or in consultation with a neurologist, neuromuscular specialist, or Muscular Dystrophy Association clinic.<14 years at start of therapy

    Documentation is required for the qualifying genetic diagnosis and ability to walk.

    Policy Summary
    PayerCigna
    PolicyExondys 51
    Policy CodePolicy IP0135
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 22, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of the qualifying DMD variant, ambulation, and baseline 6-minute walk test results for initial therapy.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage DetailsProvider Requirements and Denial RisksDisease and Treatment BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy Criteria
    Intravenous infusion over 35 to 60 minutes
    Infusion duration
    Infusion duration35 to 60 minutes
    RouteIntravenous infusion
    FrequencyOnce weekly
    Patient age at start of therapy
    Age at treatment initiationPatient must have been less than 14 years of age at the start of therapy.
    Applicable pathwayThis age requirement applies to patients currently receiving Exondys 51.
    Approval durationContinuation therapy may be approved for 6 months when all criteria are met.
    Six-minute walk test
    Required submissionSubmit baseline six-minute walk test (6MWT) results for initial therapy.
    Ambulation requirementThe patient must be able to walk.
    Distance thresholdThe current criterion does not state a minimum walking distance; it replaced the prior 180-meter requirement with submission of baseline 6MWT results.
    Documentation Required

    Initial Therapy Authorization

    For initial therapy, submit documentation showing that the patient meets all authorization requirements, including age, confirmed Duchenne muscular dystrophy, exon 51-skipping eligibility, ambulation with baseline 6MWT results, no prior Elevidys treatment, and specialist involvement.

    • Initial approval duration: 6 months.
    • Patient must be younger than 14 years at the start of therapy.
    Documentation Required

    Patient-Specific Supporting Documentation

    Provide patient-specific supporting documentation wherever the criteria indicate that documentation is required. Records must identify the patient and may include chart notes, laboratory tests, medical test results, claims records, prescription receipts, or other relevant information.

    • Ensure all submitted records contain patient-specific identifying information.
    Documentation Required

    Initial Genetic and Functional Documentation

    For initial therapy, document a confirmed Duchenne muscular dystrophy diagnosis caused by a pathogenic or likely pathogenic DMD-gene variant amenable to exon 51 skipping, along with the patient's ability to walk.

    • Include the required genetic documentation.
    • Document current walking ability.
    Documentation Required

    Continuation Documentation

    For continuation therapy, document the qualifying DMD-gene variant and that the patient remains able to walk. The patient must also have been younger than 14 years when therapy started and remain under appropriate specialist care.

    • Continuation approval duration: 6 months.
    Documentation Required

    Genetic Confirmation

    Submit genetic test results or other acceptable records confirming a pathogenic or likely pathogenic variant in the DMD gene that is amenable to exon 51 skipping.

    • The genetic confirmation must support the Duchenne muscular dystrophy diagnosis and exon 51-skipping eligibility.
    Documentation Required

    Ambulation and Baseline 6MWT

    Document that the patient is able to walk and submit baseline six-minute walk test (6MWT) results for initial therapy requests.

    • Baseline 6MWT results are required with the initial authorization request.
    • Do not substitute the prior 180-meter wording for the current requirement; the policy requires walking ability plus submission of baseline 6MWT results.
    Billing Rule

    Use Covered Codes

    Use the applicable covered diagnosis and procedure codes when submitting claims. Claims for services not accompanied by covered codes, or billed for conditions not covered by the policy, may be denied as not covered.

    • Verify that codes are the most appropriate codes in effect on the submission date.
    Denial Risk

    Failure to Meet Eligibility Criteria

    Failure to satisfy eligibility requirements may result in noncoverage, including failure to document the required age, confirmed qualifying DMD variant, ambulation, specialist involvement, or other applicable initial or continuation criteria.

    • Review every criterion before submitting the request.
    • Missing required documentation may prevent approval.
    Denial Risk

    Prior Elevidys Treatment

    An initial-therapy request may be denied when the patient has previously received Elevidys. Confirm treatment history before submitting the request.

    • The initial-therapy criterion requires that the patient has not received Elevidys.
    Denial Risk

    Concurrent Exon-Skipping Therapy

    Concurrent use of Exondys 51 with another exon-skipping agent for Duchenne muscular dystrophy is considered not medically necessary because clinical evidence does not support concurrent exon-skipping therapy.

    • Examples include Amondys 45, Viltepso, and Vyondys 53.
    Denial Risk

    Failure to Meet Initial Therapy Criteria

    An initial-therapy request may be denied when the diagnosis of Duchenne muscular dystrophy is not confirmed by a qualifying pathogenic or likely pathogenic DMD-gene variant, or when other initial-therapy requirements are not met.

    • Confirm age at therapy start, exon 51-skipping eligibility, ambulation, baseline 6MWT submission, no prior Elevidys treatment, and specialist prescribing or consultation.
    Variant amenable to exon 51 skipping
    TermVariant amenable to exon 51 skipping.
    DefinitionA DMD gene variant for which exon 51 skipping is an appropriate molecular strategy.
    Documentation relevanceCoverage requires confirmation of a pathogenic or likely pathogenic DMD gene variant amenable to exon 51 skipping.
    Age <14 years at start of therapy; baseline 6MWT results required

    Documentation is required for the genetic diagnosis, ambulation, and baseline 6MWT results.